Evaluation of platelet aggregometry in dogs using the Multiplate platelet analyzer: impact of anticoagulant choice and assay duration.

Clara B. Marschner, DVM; Annemarie T. Kristensen, DVM, PhD, DACVIM, DECVIM; Eva H. Spodsberg, DVM and Bo Wiinberg, DVM, PhD

In the February 2012 issue (volume 22(1):107–115), on page 108 of the article entitled “Evaluation of platelet aggregometry in dogs using the Multiplate platelet analyzer: impact of anticoagulant choice and assay duration” by Drs. Marschner, Kristensen, Spodsberg and Wiinberg, there were some omissions that the authors would like to correct.

Page 108, first column, first paragraph, fourth sentence should have read: “Furthermore, aggregation in the Multiplate takes place on surfaces, which is a major difference compared to methods such as Born aggregometry and single platelet counting in which platelets aggregate with each other in the liquid phase.§ Such spontaneous aggregation presumable happens only in severely ill patients, as coagulation and platelet aggregation in vivo usually only take place on surfaces such as damaged endothelium.§

Page 108, second column, first paragraph, second sentence should have read: “The term ‘multiplate” refers to the multiple electrodes in the disposable test cell, multiple channels of the instruments, as well as multiple test procedures available.§” The fourth sentence should have read : “The standard test cell uses a sample volume of only 300 μL of whole blood . For research use a mini test cell is available with sample volume of 175 μL, making it suitable for use in small animals.§

Page 108, second column, first paragraph, eighth sentence should have read: “According to the Multiplate manufacturer's website, the ‘Multiplate continuously records platelet aggregation as an increase in impedance, which is transformed into arbitrary aggregation units (AU) and plotted against time (Figure 1). Three parameters are calculated: the most important parameter being the area under the aggregation curve (AUC), which is affected by the total height of the aggregation curve as well as by its slope and is best suited to express the overall platelet activity. Two more parameters are calculated for research use: the ’aggregation’ is the height of the curve and the ’velocity’ is the maximum slope of the curve. The parameters calculated by the software include the mean values of the parameters determined with each curve.’§

Page 108, second column, second paragraph, second sentence should have read: “The manufacturer's website also states that ‘ADPtest: Adenosine diphosphate (ADP)-induced platelet activation sensitive to clopidogrel, prasugrel and other ADP receptor antagonists. ADPtest HS: High sensitivity ADPtest with co-stimulation of platelet aggregation with ADP and prostaglandin E1, especially for the sensitive detection of clopidogrel in heparinized blood. ASPItest: Cyclooxygenase dependent aggregation (using arachidonic acid [AA]), sensitive to aspirin, non-steroidal anti-inflammatory drugs (NSAIDs) and other inhibitors of platelet cyclooxygenase. TRAPtest: Platelet stimulation via the thrombin receptor (using TRAP-6), sensitive to IIbIIIa receptor antagonists in people, but demonstrated to work in dogs.9 COLtest: Collagen (COL)- induced aggregation. RISTOtest: vWF and GpIb dependent aggregation (using ristocetin as agonist). Control material: ASA Control (Aspirin (ASA) for in vitro analysis), GpIIbIIIa antagonist (for in vitro analysis), liquid quality control kit.’§

In addition, the figure legends for Figures 1 and 2 should also have stated: “Reproduced with permission from Verum Diagnostica GmbH, Munich, Germany”


  1. Top of page
  2. Reference